The complaint filed against the NASDAQ-listed company claims violations of the Securities Exchange Act of 1934. According to the allegations, PROCEPT BioRobotics pulled sales forward from future periods through heavy discounting, which resulted in a significant inventory glut. These actions allegedly rendered the company's public financial statements materially misleading to shareholders throughout the two-year class period.
In section Releases
Investors File Class Action Against PROCEPT BioRobotics Over Revenue Claims
Investors who purchased PROCEPT BioRobotics shares between February 28, 2024, and February 25, 2026, face a critical September 22 deadline to join a securities class action. The lawsuit alleges that the company engaged in aggressive discounting practices to artificially inflate revenue figures, ultimately misleading the market about its true financial health.
The DJS Law Group, led by David J. Schwartz, is representing the class and seeking individuals who suffered losses during this window. While investors may apply for lead plaintiff status, participation in potential financial recovery does not require this formal appointment. The firm, which maintains a practice focused on securities litigation and corporate governance, is currently coordinating with affected shareholders to consolidate claims before the court-mandated cutoff.
Comments (0)
No comments yet. Be the first!